Psychedelics are either a mental-health revolution or overhyped snake oil, depending who you ask — and both camps are overconfident. The honest picture is specific, promising, genuinely uncertain, and moving fast. Here's where psilocybin, MDMA, and ketamine actually stand, dated, because this is the rare topic where last year's answer is already wrong.
By Jared Ohman8 min readLast updated June 2026Source: THF Research (dated)
Real, growing evidence for specific uses; not a proven miracle. Date every claim — this is the rare topic where last year's answer is already out of date.
— The Human Frequency (current as of mid-2026)
SHORT ANSWER
As of mid-2026, the evidence for psychedelic-assisted therapy is promising but unsettled, and varies sharply by compound. Ketamine is already FDA-approved as an anesthetic, and its derivative esketamine is approved for treatment-resistant depression — the most established option. MDMA for PTSD was rejected by the FDA (a complete response letter in 2025, after a 2024 advisory committee voted against it), though related compounds are being pursued. Psilocybin is now the leading candidate for approval as a classic psychedelic: COMPASS Pathways reported two positive Phase 3 trials for treatment-resistant depression (2025 and early 2026), with a potential FDA decision around late 2026 or early 2027. Regulatory acceleration in 2026 has compressed review timelines. The honest summary: real, growing evidence for specific uses; not a proven miracle; date every claim because the landscape shifts quarterly.
GET THE FREE PRINTABLE ↓One page, wallet-card layout. Free. One email below, no spam, unsubscribe in a click.
The problem
You've heard psychedelics will cure depression, heal trauma, and revolutionize mental health. You've also heard they're dangerous hype sold by true believers. Both messages are loud, both are overconfident, and neither helps you understand what's actually known — especially if you or someone you love is suffering and wondering whether this is a real option.
The honest picture is more specific than either camp, and it has one unusual feature: it changes fast. So this page is dated on purpose.
The mechanism — current as of mid-2026
The evidence varies sharply by compound, so lumping "psychedelics" together is the first mistake.
Ketamine is the most established: already FDA-approved as an anesthetic, with its derivative esketamine approved for treatment-resistant depression. It's the one with a real clinical track record now.
Psilocybin is the leading classic-psychedelic candidate. COMPASS Pathways reported two consecutive positive Phase 3 trials for treatment-resistant depression (2025 and early 2026), hitting primary endpoints with high statistical significance, with a possible FDA decision around late 2026 or early 2027 — which would make it the first classic psychedelic approved.
MDMA for PTSD hit a wall: an FDA advisory committee voted against it in 2024, and the FDA issued a complete response letter (rejection) in 2025, citing trial-design and data-integrity concerns — a reminder that promising results and approval are different bars. Related compounds are being pursued.
Regulatory timelines accelerated in 2026 (priority review pathways compressing approval windows). The honest summary: real and growing evidence for specific uses, not a proven miracle, and genuinely uncertain at the edges — with the strong caveat that this entire paragraph could be outdated within months.
The operating system
Five ways to think about psychedelic therapy honestly.
STEP 01
Don't lump the compounds together
Ketamine, psilocybin, and MDMA are at completely different evidence and approval stages. "Psychedelics work" or "psychedelics are hype" are both too coarse to be true. Ask about the specific compound for the specific condition.
The right question is never "do psychedelics work?" but "what's the evidence for compound X in condition Y, as of when?"
STEP 02
Match the compound to the condition
The evidence is condition-specific: psilocybin for treatment-resistant depression, ketamine/esketamine for treatment-resistant depression (approved now), MDMA aimed at PTSD (currently not approved). General enthusiasm doesn't transfer across conditions.
Strong evidence for one use is not evidence for every use. The strongest cases are narrow and specific.
STEP 03
Respect the rejection as data
MDMA's FDA rejection isn't proof it doesn't work — it's a signal that rigorous review found real problems worth taking seriously (trial design, data integrity). Promising results and a safe, approvable treatment are different things, even for something people desperately want.
When a treatment you're rooting for gets rejected, that's the system doing its job, not necessarily the science failing.
STEP 04
Hold promise and uncertainty together
Resist both the hype and the dismissal. The accurate stance is: genuinely promising for specific uses, not proven, with real open questions about durability, safety, and who it helps. That's a less exciting headline and a more honest one.
"Promising and unproven" is not a hedge — it's the precise, current truth. Both halves matter.
STEP 05
Date every claim, and re-check
This field changes quarterly. Whatever you read — including this page — note its date and verify the current status before acting on it, especially for medical decisions. And make any actual treatment decision with a qualified clinician, never from a wiki page.
If a psychedelic-therapy claim has no date attached, treat it as unreliable. The date is part of the fact.
The printable: the honest snapshot
Print it. Promising, specific, unproven, fast-moving. Date everything.
PSYCHEDELIC THERAPY · MID-2026
Promising. Specific. Unproven. Fast-moving.
KETAMINE
Approved (anesthetic; esketamine for treatment-resistant depression). Most established.
PSILOCYBIN
Two positive Phase 3 trials (depression). Leading candidate; decision ~late 2026/early 2027.
MDMA
FDA rejection 2025 (PTSD) — trial-design/data concerns. Not approved.
THE STANCE
Match compound to condition. Promise + uncertainty. Date every claim.
Partly, as of mid-2026. Ketamine is approved as an anesthetic and its derivative esketamine is approved for treatment-resistant depression. MDMA-assisted therapy for PTSD was rejected by the FDA (a 2025 complete response letter following a 2024 advisory vote against it). Psilocybin is not yet approved but is the leading candidate, with a possible decision around late 2026 or early 2027. This is a fast-moving area — verify the current status before relying on it.
Does psilocybin work for depression?
The evidence is increasingly strong for treatment-resistant depression specifically. COMPASS Pathways reported two consecutive positive Phase 3 trials (2025 and early 2026) hitting their primary endpoints with high statistical significance, which is why psilocybin is the leading candidate for FDA approval. 'Increasingly strong evidence for a specific use' is accurate; 'proven cure-all' is not.
Why was MDMA therapy rejected if the early results looked good?
The FDA's concerns centered on trial-design and data-integrity issues (including questions about blinding and conduct), not simply the effect size — an advisory committee voted against approval in 2024 and the FDA issued a complete response letter in 2025. This is a useful reminder that promising early results and regulatory approval are different bars, and that rigorous review matters even for treatments people badly want.
Did this help?
One signal helps the next page get sharper. Optional note if you want to add detail.
Thanks. I read every one. — Jared
Something went sideways. Try again in a minute.
Continue the wiki
More operating systems most readers of this page also need.
The breath protocol with the strongest evidence in any 2023 anxiety RCT (Stanford). One-page printable, free.
One email. The printable lands in your inbox. Unsubscribe in a click, no spam.
SOURCES & CITATIONS▾
This page is a dated snapshot (mid-2026) of a fast-moving field. Sources:
FDA actions on MDMA-assisted therapy for PTSD (2024 advisory committee vote against; 2025 complete response letter to Lykos Therapeutics).
COMPASS Pathways Phase 3 trials of COMP360 psilocybin for treatment-resistant depression (positive results 2025 and early 2026).
FDA approval status of ketamine and esketamine (Spravato) for treatment-resistant depression; NIDA overview of psychedelic and dissociative drugs as medicines.
This is an orientation, not medical advice, and is current only as of its date. Make treatment decisions with a qualified clinician. In a crisis, contact the 988 Suicide and Crisis Lifeline (call or text 988).